# Huimei Technology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/huimei-technology

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.huimei.com
- Total disclosed funding: $81M
- Latest round: Series D (Jan 25, 2024)
- Investors on record: 7

## About

Established in 2015 and based in Beijing, China, Huimei Technology is a healthcare company that provides medical artificial intelligence solutions. The company has won the VB Find Award, the Top 10 Chinese Medical Informatization Enterprises in 2022, and so on. As of June 2023, its artificial intelligence solution has been applied in nearly 700 hospitals including West China Hospital of Sichuan University, Zhongshan Hospital Affiliated with Fudan University, Xiangya Hospital of Central South University, etc. In January 2024, Huimei Technology raised series D+ funding for CNY 70 million. In August 2025, Huimei Technology raised approximately CNY 200 million in a round of venture funding co-led by new investor Shanghai Sci-Tech Innovation Center Capital and returning investor Eastern Bell Capital, with participation from new investor Shanghai Changning State-Owned Asset Management and Investment and returning investor Qiming Venture Partners.

The company has developed the hospital application Dr. Mayson that contains functions of real-time data analysis, clinical diagnosis and treatment decision-making, clinical diagnosis and treatment risk warning, etc. The product line covers oncology, respiration, cardiovascular and cerebrovascular diseases, and other fields. It also provides a clinical research platform Darwin through its CDSS technology and data capabilities. The company generates revenue from providing medical support platforms.

## Funding rounds

- Series D, Jan 25, 2024, $9.8M — NRL Capital
- Series D, Sep 26, 2023, $41M — Qiming Venture Partners, Eastern Bell Capital, Suzhou Trust, Runzhang Investment
- Series C, Aug 30, 2019, $30M — Qiming Venture Partners, HM Capital, Wuxi AppTec Group

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C, Series D
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series C
- Wuxi AppTec Group — Series C
- Eastern Bell Capital — Series D
- Suzhou Trust — Series D
- Runzhang Investment (https://capitalatlas.ai/funds/runzhang-investment) — Series D
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Series D